Compare Stocks: ZYME, ORKA, CGON, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$76.29 -1.1%	$69.99	$24.85 ▼ $79.39	$6.65B	0.23	805,454 shs	562,498 shs
MIRM Mirum Pharmaceuticals	$100.87 +1.0%	$111.14	$63.23 ▼ $130.00	$6.53B	0.52	759,186 shs	518,109 shs
ORKA Oruka Therapeutics	$113.08 +0.4%	$89.42	$14.08 ▼ $113.31	$7.35B	-0.34	792,091 shs	574,896 shs
ZYME Zymeworks	$26.07 +3.0%	$24.12	$13.48 ▼ $29.75	$1.78B	1.15	455,246 shs	650,138 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+2.77%	+0.72%	+7.32%	+21.82%	+200.04%
MIRM Mirum Pharmaceuticals	-0.80%	+1.14%	-16.01%	+4.37%	+46.96%
ORKA Oruka Therapeutics	+1.46%	+7.15%	+21.53%	+95.93%	+632.99%
ZYME Zymeworks	+0.76%	+4.76%	+4.63%	+3.73%	+76.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$76.29 -1.1%	$69.99	$24.85 ▼ $79.39	$6.65B	0.23	805,454 shs	562,498 shs
MIRM Mirum Pharmaceuticals	$100.87 +1.0%	$111.14	$63.23 ▼ $130.00	$6.53B	0.52	759,186 shs	518,109 shs
ORKA Oruka Therapeutics	$113.08 +0.4%	$89.42	$14.08 ▼ $113.31	$7.35B	-0.34	792,091 shs	574,896 shs
ZYME Zymeworks	$26.07 +3.0%	$24.12	$13.48 ▼ $29.75	$1.78B	1.15	455,246 shs	650,138 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+2.77%	+0.72%	+7.32%	+21.82%	+200.04%
MIRM Mirum Pharmaceuticals	-0.80%	+1.14%	-16.01%	+4.37%	+46.96%
ORKA Oruka Therapeutics	+1.46%	+7.15%	+21.53%	+95.93%	+632.99%
ZYME Zymeworks	+0.76%	+4.76%	+4.63%	+3.73%	+76.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.71	Moderate Buy	$83.18	9.03% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.33	36.15% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$134.30	18.77% Upside
ZYME Zymeworks	2.82	Moderate Buy	$40.75	56.31% Upside

Current Analyst Ratings Breakdown

Latest ZYME, ORKA, CGON, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	ORKA Oruka Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
8/11/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00
8/11/2026	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$151.00
8/10/2026	ZYME Zymeworks	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $44.00
8/10/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	ZYME Zymeworks	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$46.00
8/7/2026	ZYME Zymeworks	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$37.00 ➝ $40.00
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00
8/7/2026	CGON CG Oncology	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $85.00
8/7/2026	ZYME Zymeworks	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $32.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$6.23M	1,085.80	N/A	N/A	$9.33 per share	8.18
MIRM Mirum Pharmaceuticals	$618.07M	10.60	$0.05 per share	1,974.14	$6.12 per share	16.48
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A
ZYME Zymeworks	$37.13M	49.83	N/A	N/A	$3.59 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	N/A
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	N/A
ZYME Zymeworks	-$81.13M	-$2.02	N/A	651.75	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest ZYME, ORKA, CGON, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
ORKA Oruka Therapeutics	N/A	38.51	38.51
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
MIRM Mirum Pharmaceuticals	N/A
ORKA Oruka Therapeutics	56.44%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
MIRM Mirum Pharmaceuticals	8.32%
ORKA Oruka Therapeutics	23.49%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	88.64 million	84.39 million	Optionable
MIRM Mirum Pharmaceuticals	140	64.93 million	59.53 million	Optionable
ORKA Oruka Therapeutics	N/A	66.21 million	50.66 million	N/A
ZYME Zymeworks	460	70.96 million	47.18 million	N/A

ZYME, ORKA, CGON, and MIRM Headlines

Recent News About These Companies

Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)

August 14, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Edgewise Therapeutics (EWTX)

August 14, 2026 | theglobeandmail.com

FY2026 EPS Estimates for Zymeworks Cut by HC Wainwright

August 13, 2026 | americanbankingnews.com

Q3 Earnings Estimate for Zymeworks Issued By HC Wainwright

August 12, 2026 | marketbeat.com

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

August 11, 2026 | zacks.com

HC Wainwright Issues Negative Outlook for Zymeworks Earnings

August 11, 2026 | marketbeat.com

Zymeworks Steps Up Investor Outreach with September Conference Lineup

August 11, 2026 | tipranks.com

Zymeworks Announces Participation in Upcoming Investor Conferences

August 11, 2026 | financialpost.comF

Zymeworks Inc. to Participate in Upcoming Investor Conferences in September

August 11, 2026 | quiverquant.comQ

Zymeworks (NASDAQ:ZYME) Update Puts Antibody Strategy In Focus

August 9, 2026 | kalkinemedia.comK

Truist Financial Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) Stock

August 9, 2026 | americanbankingnews.com

Assenagon Asset Management S.A. Has $32.73 Million Stake in Zymeworks Inc. $ZYME

August 9, 2026 | marketbeat.com

Wells Fargo Remains a Buy on Zymeworks (ZYME)

August 8, 2026 | theglobeandmail.com

HC Wainwright Has Negative Outlook for Zymeworks Q3 Earnings

August 8, 2026 | americanbankingnews.com

Zymeworks (NASDAQ:ZYME) Issues Earnings Results, Misses Expectations By $0.05 EPS

August 7, 2026 | marketbeat.com

Zymeworks (NASDAQ:ZYME) Stock Price Expected to Rise, Truist Financial Analyst Says

August 7, 2026 | marketbeat.com

What is HC Wainwright's Forecast for Zymeworks Q2 Earnings?

August 7, 2026 | marketbeat.com

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

What is HC Wainwright's Estimate for Zymeworks Q3 Earnings?

August 6, 2026 | marketbeat.com

Segall Bryant & Hamill LLC Takes Position in Zymeworks Inc. $ZYME

August 6, 2026 | marketbeat.com

A Post Acquisition Look At Zymeworks

August 5, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME, ORKA, CGON, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

$76.29 -0.82 (-1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$76.18 -0.11 (-0.14%)

As of 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$100.87 +1.04 (+1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$100.58 -0.29 (-0.28%)

As of 07:34 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Oruka Therapeutics NASDAQ:ORKA

$113.08 +0.42 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$111.70 -1.38 (-1.22%)

As of 07:30 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Zymeworks NASDAQ:ZYME

$26.07 +0.76 (+3.00%)

Closing price 04:00 PM Eastern

Extended Trading

$26.02 -0.05 (-0.21%)

As of 07:36 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, ORKA, CGON, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, ORKA, CGON, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, ORKA, CGON, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME, ORKA, CGON, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, ORKA, CGON, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, ORKA, CGON, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, ORKA, CGON, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME, ORKA, CGON, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools